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Background. Chronic alcohol-related liver disease (ALD) is mediated by insulin resistance, mitochondrial dysfunction,
inflammation, oxidative stress, and DNA damage. Recent studies suggest that dysregulated lipid metabolism with accumulation
of ceramides, together with ER stress potentiate hepatic insulin resistance and may cause steatohepatitis to progress. Objective. We
examined the degree to which hepatic insulin resistance in advanced human ALD is correlated with ER stress, dysregulated lipid
metabolism, and ceramide accumulation. Methods. We assessed the integrity of insulin signaling through the Akt pathway and
measured proceramide and ER stress gene expression, ER stress signaling proteins, and ceramide profiles in liver tissue. Results.
Chronic ALD was associated with increased expression of insulin, IGF-1, and IGF-2 receptors, impaired signaling through IGF-1R
and IRS1, increased expression of multiple proceramide and ER stress genes and proteins, and higher levels of the C14, C16, C18,
and C20 ceramide species relative to control. Conclusions. In human chronic ALD, persistent hepatic insulin resistance is associated
with dysregulated lipid metabolism, ceramide accumulation, and striking upregulation of multiple ER stress signaling molecules.
Given the role of ceramides as mediators of ER stress and insulin resistance, treatment with ceramide enzyme inhibitors may help
reverse or halt progression of chronic ALD.
1. Introduction
Worldwide, alcohol abuse is one of the leading causes
of morbidity and mortality from chronic liver disease
[1, 2]. In its initial stages, alcohol-related liver disease
(ALD) is characterized by hepatic steatosis, which is largely
reversible. However, with continued chronic alcohol abuse,
liver disease can progress through stages of steatohepatitis,
followed by fibrosis, and then cirrhosis, and in the late
stages, it may culminate in liver failure or hepatocellular
carcinoma [3]. Previous studies linked chronic ALD to the
combined eﬀects of hepatic insulin resistance and toxicity
mediated by inflammation, oxidative stress, mitochondrial
dysfunction, or acetaldehyde-induced adduct formation [4–
7]. The consequences include impairments in hepatocellular
survival, energy metabolism, and capacity to regenerate
and remodel after injury. Together, these responses serve
as potent stimuli for stellate cell activation and attendant
fibrogenesis [8].
Recent studies have linked insulin resistance with inflam-
mation and oxidative stress to dysregulated lipid metabolism
and increased ceramide generation [9–11]. However,
ceramides can further impair insulin signaling, mito-
chondrial function, and cell viability [12, 13]. Ceramides
comprise a family of simple sphingolipids generated from
fatty acid and sphingosine [13–15]. Although ceramides
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are present at low levels within biological membranes, they
make important contributions to cell membrane structure by
participating in lipid raft formation. In addition, ceramides
exert diverse regulatory eﬀects on cell signaling pathways
that mediate growth, proliferation, motility, adhesion,
diﬀerentiation, senescence, and apoptosis [12, 13, 16–18].
Ceramides are generated via 3 main pathways: (1) de
novo synthesis by coupling sphinganine to a long-chain fatty
acid, yielding dihydroceramide; (2) hydrolysis of complex
sphingolipids such as sphingomyelin or glycosphingolipids;
(3) recycling after acylation of sphingosine, utilizing the “sal-
vage pathway” [16, 17]. Ceramides cause insulin resistance
by activating proinflammatory cytokines, inhibiting trans-
mission of signals through phosphatidyl-inositol-3 kinase
(PI3K) and Akt [19–22], and activating protein phosphatase
2A (PP2A) [23, 24]. Furthermore, ceramides can promote
apoptosis by activating protein kinase C, PP1, caspases,
and cathepsin D [16, 18]. Therefore, dysregulated lipid
metabolism promoted by insulin resistance leads to increased
generation of ceramides that exacerbate insulin resistance,
inflammation, tissue injury, and cell death.
Emerging evidence suggests that ceramide production
can be modulated by ethanol exposure, and that some of
the hepatotoxic and degenerative eﬀects of ethanol may be
mediated by ceramide accumulation in liver. For example,
ethanol increases ceramide levels by activating acidic sphin-
gomyelinase [25], and ethanol-exposed hepatocyte cultures
exhibit reduced levels of sphingomyelin and sphingosine,
and increased levels of ceramide [26]. The findings that (1)
mice deficient in acidic sphingomyelinase are resistant to
ethanol-induced hepatic steatosis [27], and (2) ceramides
contribute to the inhibitory eﬀects of ethanol on AMPK
phosphorylation [28] suggest that ceramides generated in
ethanol exposed livers may cause liver injury.
Increased ceramide production can lead to endoplasmic
reticulum (ER) stress and thereby contribute to the pro-
gression of ALD. ER stress can potentiate insulin resistance
and lipolysis leading to increased ceramide production [29–
32] and worsening of inflammation and insulin resistance.
ER stress is caused by disruption of homeostatic mecha-
nisms, causing unfolded proteins to accumulate, and reactive
oxygen species (ROS) to form [33]. Normally, the ER
adapts to stress by activating the unfolded protein response
(UPR) [34, 35], which quickly increases the levels of ER
stress sensor proteins including inositol-requiring enzyme 1
(IRE1), PKR-like ER-localized eIF2α kinase (PERK), and the
activating transcription factor 6α (ATF-6α; ER membrane-
anchored transcription factor). PERK and IRE1 activate
ER stress networks by transmitting signals in response to
protein misfolding or unfolding. PERK promotes a global
arrest of protein synthesis by stimulating phosphorylation of
eukaryotic translation initiation factor 2α (eIF2α), selective
translation of ATF4, and upregulation of the transcription
factor C/EBP homologous protein CHOP. IRE1α promotes
alternative splicing of XBP1, leading to increased transcrip-
tion of chaperones and ER-associated protein degradation
(ERAD) machinery. Activated ATF-6 promotes increased
synthesis of chaperones and other components of the folding
and ERAD machinery. Prolonged activation of the UPR
induces a pathological response leading to inflammation,
injury, steatosis, and apoptosis [34, 36].
The above discussion highlights the importance of
insulin resistance in ALD, and the probable interrelationship
among insulin resistance, increased ceramide generation,
and ER stress. We hypothesize that progressive ALD is
mediated by the establishment of a harmful positive feedback
loop whereby insulin resistance leads to lipolysis and toxic
ceramide generation, which promotes ER stress, and both
toxic ceramides and ER stress worsen insulin resistance.
The present work examines the potential contributions of
sustained insulin resistance, ER stress, and dysregulated
lipid metabolism with increased activation of proceramide
mechanisms and ceramide accumulation in human livers
with chronic ALD.
2. Materials and Methods
2.1. Materials. Antibodies to ER stress markers were pur-
chased from Cell Signaling (Danvers, MA). The Akt Total
and Phospho 7-Plex Panels, Taqman Gene expression master
mix, and Amplex Red Sphingomyelinase assay kit were
purchased from Invitrogen (Carlsbad, CA). Bead-based
magnetic immunoassays for cytokines quantification were
from Biorad (Hercules, CA). MaxiSorp 96-well plates used
for ELISAs were from Nunc (Thermo Fisher Scientific;
Rochester, NY). Superblock-TBS, horseradish peroxidase-
conjugated antibodies, and SuperSignal Enhanced Chemi-
luminescence Reagents were from Pierce Chemical Co
(Rockford, IL). QIAzol Lysis Reagent for RNA extraction
was obtained from Qiagen, Inc (Valencia, CA). The AMV
1st Strand cDNA Synthesis kit, the Universal Probe Library
probes, and Reference gene assays were purchased from
Roche Applied Science (Indianapolis, IN). The Serum
Triglyceride Determination kit, monoclonal anti-ceramide,
and synthetic oligodeoxynucleotides were purchased from
Sigma-Aldrich Co (St. Louis, MO). All other monoclonal
antibodies and immunodetection reagents were purchased
from Abcam (Cambridge, MA), Upstate (Billerica, MA),
Vector Laboratories (Burlingame, CA), Invitrogen (Carlsbad,
CA), or Chemicon (Temecula, CA). Fine chemicals were
purchased from CalBiochem (Carlsbad, CA) or Sigma-
Aldrich (St. Louis, MO).
2.2. Source of Human Liver Tissue. Liver tissue biopsies from
patients with chronic ALD and cirrhosis were obtained from
the Liver Tissue Procurement Distribution System (NIH
Contract no. N01-DK-9-2310). Normal human control liver
biopsy tissue samples were obtained from the Lifespan-
Rhode Island Hospital Tumor Bank (Providence, RI). Con-
trol liver samples represented remnant tissue from surgical
biopsies performed for diagnosis. 10 samples were analyzed
in each group. All specimens were deidentified and their use
in this study was approved by the Lifespan Human Studies
Committee and Investigational Review Board. Snap-frozen
fresh tissues stored at −80◦C were used for RNA, protein,
and lipid studies. Formalin-fixed paraﬃn-embedded tissue
sections were stained with hematoxylin and eosin (H&E) and
with Masson’s trichrome for histological assessment.
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2.3. Quantitative Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR) Assays. RNA extracted from fresh
frozen liver using the RNeasy Mini Kit was reverse-
transcribed using random oligonucleotide primers and the
AMV 1st Strand cDNA Synthesis Kit. Gene expression
was measured in duplicate reactions with a hydrolysis
probe-based duplex qRT-PCR assay in which hypoxanthine-
guanine phosphoribosyltransferase (HPRT) was included
as a reference gene. Reactions (20 μL) contained Taqman
Gene expression master mix, 400 nM of gene-specific and
HPRT primers, and 200 nM of HPRT (Y555 labeled) and
gene of interest (FAM labeled) probes. Gene-specific primer
sequences and matched probes were determined with the
ProbeFinder Software (Roche, Indianapolis, IN) (Table 1).
PCR amplifications were initiated by a 10-minute, 95◦C
denaturation step and followed by 45–50 2-step cycles of
denaturation (15-seconds at 95◦C) and annealing/extension
(1-minute at 60◦C). The amplifications were performed in
a LightCycler 480 PCR machine (Roche, Indianapolis, IN).
Fluorescence signals corresponding to the genes of interest
were acquired in the FAM Channel (Em: 520–530 nm), and
the HPRT signal was acquired in the Y555/HEX channel
(Em: 550–568 nm). Results were analyzed using LightCycler
Software 4.0. Alternatively, gene expression was measured in
triplicate by qRT-PCR analysis using QuantiTect SYBRGreen
PCR Mix and gene-specific primer pairs [37], with results
normalized to 18S rRNA as described [10].
2.4. Enzyme-Linked Immunosorbent Assay (ELISA). Liver
homogenates were prepared in lysis buﬀer containing
50mM Tris (pH 7.5), 150mM NaCl, 5mM EDTA (pH
8.0), 50mM NaF, 0.1% Triton X-100, and protease and
phosphatase inhibitors [38]. Direct binding ELISAs were
performed in 96-well MaxiSorp plates. Protein homogenates
(100 ng/50 μL) were adsorbed to the well bottoms by
overnight incubation at 4◦C, and then blocked for 3 hours
with 1% bovine serum albumin (BSA) in TRIS buﬀered
saline (TBS). After washing, the samples were incubated
with primary antibody (0.1–0.4 μg/mL) for 1 hour at
37◦C. Immunoreactivity was detected with horseradish-
peroxidase-(HRP-) conjugated secondary antibody and
Amplex UltraRed soluble fluorophore. Fluorescence
intensity was measured (Ex 565 nm/Em 595 nm) in a
SpectraMax M5 microplate reader (Molecular Devices,
Sunnyvale, CA). Ceramide immunoreactivity was quantified
by ELISA as previously described [39].
2.5. Bead-Based Multiplex ELISA. We used bead-based mul-
tiplex ELISAs to assess the integrity of signaling through the
insulin and IGF-1 receptors, insulin receptor substrate, type
1 (IRS-1), and downstream through Akt-related pathways
using Akt Total and Phospho 7-Plex Panels. The Akt Total
7-Plex panel measured immunoreactivity to insulin receptor
(IR), IGF-1 receptor (IGF-1R), IRS-1, Akt, proline-rich Akt
substrate of 40 kDa (PRAS40), ribosomal protein S6 kinase
(p70S6K), and glycogen synthase kinase 3β (GSK-3β). The
Akt Phospho 7-Plex panel measured immunoreactivity to
pYpY1162/1163-IR, pYpY1135/1136-IGF-1R, pS312-IRS-1, pS473-Akt,
pT246-PRAS40, pTpS421/424-p70S6K, and pS9-GSK3β. Samples
containing 100 μg protein were incubated with the beads
according to the manufacturer’s protocol. Captured antigens
were detected with secondary antibodies and phycoerythrin-
conjugated anti-rabbit IgG. Proinflammatory cytokine levels
in liver weremeasured with a 21-plex bead-based immunoas-
say (200 μg protein/well). Plates were read in a Bio-Plex 200
system (Bio-Rad, Hercules, CA).
2.6. Liquid Chromatography, Tandem Mass Spectrometry
(LC-MS-MS) for Quantification of Ceramides in Liver Tissue.
Lipids were extracted for ceramide profiling as described
[40, 41]. In brief, 60–70mg of fresh frozen tissue were
homogenized in 10 volumes of ice cold phosphate-buﬀered
saline (PBS). 200 μL of homogenate were extracted with
isopropanol : water : ethyl acetate (30 : 10 : 60 by volume).
The combined extracts were transferred to clean glass
centrifuge tubes and evaporated at room temperature
in a SpeedVac evaporator (Model SPD1010 Speed Vac
System, Thermosavant, Holbrook, NY). The residues
were redissolved in 100 μL of methanol, vortex-mixed
and then centrifuged; 5 μL were injected in the analytical
column. The system comprised a binary pump and
autosampler (Shimadzu, Kyoto, Japan) coupled to an
API 3200 triple quadruple mass spectrometric detector
(AB Sciex, Toronto, Ontario, Canada), equipped with a
Turbo V source electrospray ionization (ESI) probe. The
chromatographic data were collected and analyzed using
the Analyst package (version 1.4.1., AB Sciex). Multiple
reaction monitoring (MRM) scanning was used for mass
spectral detection and quantification of C14-Ceramide
(N-myristoyl-D-erythro-sphingosine), C16-Ceramide (N-
palmitoyl-D-erythro-sphingosine), C18-Ceramide (N-
stearoyl-D-erythro-sphingosine), C20-Ceramide (N-arachy-
donyl-D-erythro-sphingosine) and C24-Ceramide (N-ligno-
ceroyl-D-erythro-sphingosine). C17-Ceramide (Heptade-
canoyl-D-erythro-sphingosine) was used as an internal
standard.
Thermo-Hypersil GOLD PFP (50 × 2.1mm, 3.0 μm)
analytical columns were used for chromatographic sepa-
ration of the lipids using Buﬀer A (1.0mmol/L ammo-
nium acetate, 0.5% formic acid, v/v/v) and Buﬀer B
(1.0mmol/L ammonium acetate, 0.5% formic acid, HPLC-
grade methanol, v/v/v). The mobiles phase was comprised
of solvent mixtures: A : B 50 : 50 (v/v) at 0.0min; A : B
20 : 80 (v/v) for 0.01–8.0min; A : B 5 : 95 (v/v) for 8.1–
15.0min; A : B 5 : 95 (v/v) for 15.1–20.0min; A : B 5 : 95
(v/v) for 20.1-20.2min; followed by column equilibration
at A : B 50 : 50 (v/v) for five minutes, giving an injection
cycle of 25 minutes. The flow rate was 250 μL/min. Spe-
cific pairs of precursor/product ions were as follows: the
ion transitions were C14-Ceramide (510.5→ 492.4), C16-
Ceramide (538.8→ 520.5), C17-Ceramide (552.6→ 534.4),
C18-Ceramide (566.4→ 548.4), C20-Ceramide (594.7→
576.2), and C24-Ceramide (650.6→ 632.5). The retention
times for C14-Ceramide, C16-Ceramide, C17-Ceramide,
C18-Ceramide, C-20-Ceramide, and C24-Ceramide were
9.4, 10.0, 10.4, 10.7, 11.1, and 12.1 minutes, respectively.
The ionization was set at electrospray positive ion mode
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Table 1: List of primers used for qRT-PCR analysis of gene expression.
Primer Sequence (5′ → 3′) Position (mRNA) Amplicon size (bp) UPL probe no.
HERP FOR ACTGTCGTTGCAGAGATTGC 322 107 70
HERP REV GTTCGGTCTCGGACTCCAT 410
GRP-78/Bip FOR TGAAGGTGAAAGACCCCTGA 1654 107 15
GRP-78/Bip REV CAAAGGTGACTTCAATCTGTGG 1739
EDEM-1 FOR GCTGAGTGATTACCTTAGCCACA 5504 72 15
EDEM-1 REV TGGACAGGAAAGCTCAGGAT 5556
WARS FOR CTGGACGGGTGGACTTAGC 2667 77 74
WARS REV GAGGCCTGCCTAGACATCTG 2724
PDI FOR TGAGGTCTGCGGAAGGTC 2226 95 16
PDI REV TCCGAGATACTGTCGTTTGTTG 2299
P58IPK FOR CTGAAGGAGCAAGAGACCATC 2182 76 87
P58IPK REV TTAATCCAAAGTCTAAGCCTGGATA 2233
BAX FOR TGACCCCTGACCTCACTGT 763 82 29
BAX REV TGAGCAATTCCAGAGGCAGT 825
CHOP FOR GTCATTGCCTTTCTCCTTCG 192 61 33
CHOP REV GTCCTCATACCAGGCTTCCA 233
ATF-4 FOR AAGGAGTTCGACTTGGATGC 1156 78 85
ATF-4 REV ATCCAACGTGGTCAGAAGGT 1214
CERS1 FOR CAATGTGGGCATCCTTGTG 669 61 4
CERS1 REV GGTGAACTCAAGCTGCACG 711
CERS2 FOR ACTTCTGGTGGGAACGTCTG 370 73 27
CERS2 REV ACACGTCCATCTCGGTCTTC 423
CERS4 FOR GCAGGTGATACACCACTTCG 944 91 62
CERS4 REV TAACAGCAGCACCAGAGAGC 1015
CERS5 FOR CATATGCGTGAGTTTCATTGC 1440 95 57
CERS5 REV GTGGAACTAAGGTGGGTTCAGT 1513
CERS6 FOR GCTGGTTTCGACAAAGACG 468 60 2
CERS6 REV TCTCACAGAACCTCGTCAGC 508
UGCG FOR GATCAGGTGGACCAAACTACG 1109 71 4
UGCG REV AGCATTCTGAAATTGGCTCAC 1159
GM3 Syn FOR TGCTGCTGATACTGGGTCTG 1710 77 26
GM3 Syn REV CAACAGAGAAGGGTTGTGACC 1766
SMPD-1 FOR GCACACCTGTCAATAGCTTCC 1142 78 52
SMPD-1 REV TGGCCATCGCTTCATAGAG 1201
SMPD-3 FOR AGGACCTGCTGTCTGCTGTC 3956 76 79
SMPD-3 REV TTGCAGCTCAATGGGTGAC 4013
SPTLC-1 FOR CGCGCTACTTGGAGAAAGA 1324 77 52
SPTLC-1 REV CTCTGTTTGTTCCACCGTGA 1381
SPTLC-2 FOR ATCGGTGTCGTTGTGGTTG 1659 82 21
SPTLC-2 REV TGGTATGAGCTGCTGACAGG 1721
CERD2 FOR GACCATGTCTGGACGAAGACTTC 1626 77 34
CERD2 REV CAACAGTCATGTTCTGCATCCC 1681
CERD3 FOR GGCAGTGGCTATAGCATATGG 367 85 12
CERD3 REV AGACCAGGCGGATGAACTG 433
Abbreviations: CERS: ceramide synthase; SMPD: sphingomyelin phosphodiesterase; UGCG: UDP glucose ceramide glycosyltransferase; SPTLC: serine
palmitoyl transferase; CERD: ceramidase; GM3Syn: GM3-synthase; EDEM: ER degradation-enhancing α-mannosidase-like protein; CHOP: C/EBP
homologous protein; p58IPK: inhibitor of interferon-induced and double stranded RNA activated kinase; GRP78: glucose regulated protein 78; ATF:
activating transcription factor-4; HERP: homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1; WARS: tryptophanyl-
tRNA synthetase.
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and at a temperature of 150◦C utilizing nitrogen for the
drying and collision gas (curtain gas, 10 psi; collision gas,
3 psi; ionspray voltage, 5500V; ion source gas 1, 25 psi;
ion source gas 2, 25 psi). Separate stock solutions of all
compounds each containing 1.0mM were prepared in
methanol. Working standard solutions of combined analytes
were prepared by serial dilution in methanol. Calibration
standards were prepared in concentrations ranging from
0.5 μM to 500 μM (0.1 μM, 0.5 μM, 1 μM, 5 μM, 10 μM,
50 μM, 100 μM, 500 μM). The internal standard was used at
a final concentration of 20 nM.
2.7. Statistical Analysis. Data depicted in box plots reflect
group medians (horizontal bar), 95% confidence interval
limits (upper and lower box limits), and range (whiskers).
Tabulated data reflect means ± SEMs for each group. Data
were analyzed using GraphPad Prism 5 software (GraphPad
Software, Inc., San Diego, CA), and intergroup comparisons
were made using Student’s t-tests. Computer software gener-
ated P values are shown over the graph panels or in the tables.
3. Results
3.1. ALD Features. The 10 control livers all exhibited the nor-
mal chord-like architecture and were free of inflammation,
steatosis, fibrosis, and cholestasis. Livers from the 10 chronic
alcoholics had micronodular cirrhosis with steatohepatitis,
apoptotic bodies, disorganization of the normal chord
architecture, bile duct proliferation, and cholestasis. None
of the livers exhibited dysplasia or hepatocellular carcinoma.
Corresponding with the hepatic steatosis, the livers with
ALD had significantly increased levels of neutral lipids as
demonstrated with the Nile Red assay (Control: 9.41 ±
1.23 (FLU/g), ethanol: 13.35 ± 1.45 (FLU/g), P = 0.03). In
contrast, mean triglyceride content was similar in the ALD
and control livers (Control: 24.89 ± 2.95 (μg/mg), ethanol:
24.38 ± 3.21 (μg/mg)).
3.2. Cytokine Activation in Chronic ALD (Table 2). We used
a 21-plex bead-based assay to measure proinflammatory
cytokine and chemokine levels in relation to chronic ALD.
Contrary to what might have been expected, chronic ALD
was not associated with significantly increased levels of
cytokines or chemokines in liver. Instead, the mean levels of
proinflammatory cytokines IL-10, SDF-1α, MCP, IL-1β, IL-6
and TRAIL, and pro-fibrogenic cytokines VEGF, PDGF, and
β-FGF were significantly lower in the chronic ALD relative
to control livers. In contrast, the mean level of HGF, which
is progrowth and antifibrogenic was significantly elevated
in chronic ALD relative to control livers. However, qRT-
PCR analysis demonstrated higher levels of IL-1β, IL-6, and
TNF-α in the ethanol group, with significant intergroup
diﬀerences obtained with respect to IL-6 (Table 2). A similar
phenomenon was observed in experimental models of
chronic ethanol feeding [11]. The discrepancies between
mRNA and protein could be due to increased release of
newly synthesized cytokines in the context of chronic ethanol
exposure.
3.3. Chronic ALD Is Associated with Impaired Hepatic Insulin
Signaling. The qRT-PCR analyses demonstrated signifi-
cantly reduced levels of IGF-2 and IRS-4, and increased levels
of insulin, IGF-1, and IGF-2 receptor mRNA transcripts
in chronic ALD relative to control livers. In contrast, the
mRNA levels of insulin and IGF-1 polypeptide genes were
similar in the two groups (Figure 1). Multiplex ELISAs also
demonstrated significantly higher levels of insulin and IGF-1
receptor expression, and significantly reduced levels of IRS-
1 protein in the ALD group (Figure 2). Although tyrosine
phosphorylated insulin receptor levels were also increased
in the ALD group, the ratio of phosphorylated/total insulin
receptor was similar to control. In contrast, relative phospho-
rylation of the IGF-1 receptor was significantly reduced in the
ALD versus control livers. ALD was also associated with sig-
nificantly increased levels of S312 phosphorylation of IRS-1.
S312 phosphorylation of IRS-1 inhibits IRS-1 signaling [42].
Additional studies characterized the eﬀects of chronic
ALD on downstream signaling through Akt pathways.
Chronic ALD was associated with significantly increased
levels of total and phosphorylated AKT levels, but similar
levels of phospho/total Akt relative to control. ALD was
associated with significantly reduced levels of total GSK-
3β, but significantly increased Ser9 phospho/total GSK-3β,
reflecting reduced levels of GSK-3β activity. Correspond-
ingly, we detected no significant eﬀects of chronic ALD on
the total, phosphorylated or phospho/total levels of proline-
rich Akt substrate 40 kDa (PRAS 40) or p70S6 kinase, which
mediate mTOR signaling (Table 3).
3.4. Chronic ALD Is Associated with Increased Activation
of Proceramide Mechanisms in Liver. Previous studies
in experimental animal models demonstrated that
steatohepatitis from various causes, including chronic
ethanol exposure, is associated with increased proceramide
gene expression and ceramide levels in liver [10, 11].
To determine if human chronic ALD exhibits the same
abnormalities, we measured mRNA levels of proceramide
genes corresponding to the de novo synthesis (Ceramide
synthases 1, 2, 4, 5, 6, and the subunits 1 (regulatory) and 2
(catalytic) of serine palmitoyl transferase subunit (SPTLC1
and 2)), catabolic (sphingomyelin phosphodiesterases 1 and
3 (SMPD-1 and SMPD-3) and ceramidases (CERD)), and
to biosynthesis of complex sphingolipids (ganglioside GM3
synthase and UDP-glucose ceramide glucosyltransferase
(UGCG)) pathways by qRT-PCR analysis (Table 4). Chronic
ALD was associated with significantly increased expression
of CERS1, CERS5, CERS6, and SPTLC1, reflecting
increased ceramide biosynthesis, increased mRNA levels
of SMPD1 and SMPD3, corresponding to increased levels
of sphingomyelin hydrolysis, and decreased expression of
CERD2, an enzyme responsible for deacylation of ceramide
to sphingosine and fatty acids. In addition, chronic ALD
was associated with significantly increased levels of GM3
synthase and UGCG, which mediate formation of complex
sphingolipids from ceramides. We also measured acidic,
neutral, and alkaline sphingomyelinase activities using
commercial assay reagents and found significantly higher
levels of all three in ALD relative to control livers (Figure 3).
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Table 2: Eﬀects of chronic ethanol exposure on proinflammatory cytokine levels in liver tissue.
Control Ethanol P value
Protein
LIF 58.19 ± 3.02 51.27 ± 3.06
IL-10 18.20 ± 1.19 13.95 ± 0.97 0.008
MCP-1 (CCL2) 1793.48 ± 559.87 1123.61 ± 496.75 0.001
HGF 1305.97 ± 299.12 3887.81 ± 691.31 0.0001
SCF 30.14 ± 3.14 28.14 ± 1.29
SDF (CXCL12) 79.25 ± 11.76 29.75 ± 2.76 <0.0001
VEGF 195.74 ± 12.52 120.72 ± 9.74 0.0003
PDGF 111.52 ± 9.94 59.73 ± 4.69 0.0002
IL-16 2769.95 ± 244.39 3058.46 ± 219.60
GM-CSF 39.05 ± 1.29 33.54 ± 2.83
β-FGF 948.78 ± 81.77 546.07 ± 46.79 0.0005
IP-10 734.19 ± 479.61 398.13 ± 96.21
MIP-1 2279.33 ± 791.99 1177.78 ± 142.71
IL-18 365.60 ± 48.50 672.60 ± 218.45
β-NGF 41.76 ± 4.26 48.60 ± 8.14
IL-8 806.30 ± 321.41 929.34 ± 185.10
IFN-γ 6.66 ± 0.37 6.93 ± 0.55
IL-1β 123.40 ± 44.97 34.23 ± 7.75 0.028
IL-6 316.64 ± 108.93 126.60 ± 91.79 0.009
TNF-α 12.95 ± 1.03 15.93 ± 2.72
TRAIL 61.14 ± 13.65 25.67 ± 2.84 0.01
mRNA
IL-1β 0.0254 ± 0.0098 0.0341 ± 0.0112 ns
IL-6 0.0670 ± 0.027 0.2727 ± 0.1033 0.0376
TNF-α 0.0253 ± 0.005 0.04072 ± 0.010 ns
Liver protein homogenates were used to measure immunoreactivity of the indicated cytokines by multiplex ELISA. Immunoreactivity was normalized to
protein concentration and data are expressed as mean ± SEM of fluorescence light units (arbitrary). mRNA was used to measure gene expression of TNF-α,
IL-1β, and IL-6 via qRT-PCR. Results were normalized to ribosomal 18S levels measured in the same samples. Intergroup comparisons were made using t-test
and significant P values are indicated in the right columns.
3.5. Chronic ALD Results in Increased Ceramide Levels and
Altered Ceramide Profiles in Liver. We measured ceramide
immunoreactivity in liver tissue homogenates by ELISA and
quantified the levels of ceramides C14:0, C16:0, C18:0, C20:0,
and C24:0 by LC-MS/MS (Figure 3). Livers from patients
with chronic ALD were associated with significantly higher
levels of ceramide immunoreactivity relative to controls.
The LC-MS/MS studies demonstrated the most abundant
ceramide species in control human livers were C18:0,
followed by C16:0, and then C20:0 and the least abundant
was C14:0. In the chronic ALD samples, the mean levels of
C14:0, C16:0, C18:0, and C20:0 were significantly elevated
relative to control, whereas the levels of C24:0 were similar
for the two groups.
3.6. ER Stress in ALD. Steatohepatitis, ceramide accumula-
tion, and insulin resistance can each contribute to the activa-
tion of ER stress pathways, and ER stress can promote oxida-
tive injury and inflammation, which cause ALD to progress.
To determine if chronic ALD in humans is associated with
increased ER stress, we measured mRNA expression of
multiple genes that mediate ER stress at various levels within
the cascade [43]. Chronic ALD was associated with signif-
icant upregulation of the chaperone Bip/GRP78, the tran-
scription factor ATF-4, the homocysteine-responsive endo-
plasmic reticulum-resident ubiquitin-like domain mem-
ber 1 (HERP) and tryptophanyl-tRNA synthetase (WARS)
(Figure 4). ER degradation-enhancing α-mannosidase-like
1 (EDEM) and protein kinase inhibitor p58 (P58IPK)
mRNA transcripts were also elevated in the ALD group,
but the intergroup diﬀerences failed to reach statistical
significance due to the large within group variances. Finally,
since sustained UPR activation drives pathological responses
leading to apoptosis, we measured expression of BAX and
the transcription factor CHOP, and both were found to be
significantly elevated in chronic ALD.
ELISAs were used to measure immunoreactivity to
Bip/GRP78, CHOP, IRE-1α, calnexin, the oxidoreductase
ERO1α, protein disulphur isomerase (PDI), PERK, phospho
(Thr980) PERK, eIF2α, and phospho (Ser51) eIF2α. Chronic
ALD was associated with significantly increased levels of
Bip/GRP78, CHOP, IRE-1α, calnexin, ERO-1a, and PDI
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Figure 1: Eﬀects of chronic ALD on hepatic expression of insulin/IGF ligands and receptors, and IRS genes. RNA extracted from livers of
control and chronic ALD subjects (N = 8/group) was reverse transcribed, and the cDNAs were used to measure gene expression by qPCR
analysis. Graphs depict relative mRNA levels for (a) insulin, (b) insulin-like growth factor (IGF-1), (c) IGF-2, (d) insulin receptor (R), (e)
IGF-1 receptor (IGF-1R), (f) IGF-2R, (g) insulin receptor substrate-1 (IRS-1), (h) IRS-2, and (i) IRS-4. Intergroup comparisons were made
using Student’s t-tests. Significant P values are shown over the graphs.
relative to control livers. In addition, the chronic ALD
livers had significantly higher levels of PERK, p(Thr980)-
PERK, and eIF2α relative control. In contrast, levels of
phosphorylated eIF2α (Ser51) were similar for the two
groups, while the relative level of phospho/total eIF2α was
significantly reduced in the chronic ALD relative to control
group (Figure 5). Further Western blot analyses confirmed
that ER stress pathways through PERK, Bip/GRP78, and
CHOP were upregulated in chronic alcoholic livers (see
Supplementary Figure 1 in SupplementaryMaterial available
online at doi:10.1155/2012/479348).
4. Discussion
This study was designed to gain a better understanding of
the molecular pathogenesis of chronic progressive ALD in
humans by determining if the abnormalities detected were
similar to those previously identified in experimental animal
models. Therefore, we examined several interrelated aspects
of liver injury including (1) histopathology; (2) integrity
of insulin/IGF signaling through upstream and Akt down-
stream pathways; (3) activation of proinflammatory medi-
ators; (4) ceramide production, accumulation, and profiles;
(5) ER stress activation. Together, these approaches enabled
us to characterize the nature and extent of hepatocellular
dysfunction in human chronic progressive ALD. Moreover,
the findings suggest that multipronged therapeutic strategies
are needed to prevent or reduce ALD progression.
4.1. ALD Features. The histopathological studies demon-
strated that all cases of chronic ALD included in this study
had severe steatohepatitis with cirrhosis. As the livers were
obtained from patients scheduled for liver transplantation,
their clinical disease status was regarded as advanced.
The presence of active steatohepatitis with conspicuous
foci of apoptosis and necrosis indicates that the disease
process was still progressing at the time of tissue sampling,
thereby enabling us to determine the molecular and patho-
physiological processes contributing to the ongoing liver
injury and degeneration. The finding of reduced levels of
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Figure 2: Eﬀects of chronic ALD on insulin signaling mechanisms. Protein homogenates of liver were used in bead-based multiplex ELISAs
to measure immunoreactivity corresponding to (a) insulin receptor (InR), (b) IGF-1 receptor (IGF-1R), (c) IRS-1, (d) pYpY1162/1163InR,
(e) pYpY1135/1136IGF-1R, and (f) pS312IRS-1. Calculated phospho/total ratios of (g) InR, (h) IGF-1R, and (i) IRS-1 reflect relative levels of
phosphorylation. Intergroup comparisons were made using Student’s t-tests and significant P values are shown over the graphs.
Table 3: Eﬀects of chronic ALD on the integrity of the Akt signaling pathway.
Control Ethanol P value
Protein (Total)
AKT 18599.50 ± 744.87 22377.37 ± 478.47 0.0002
GSK3β 2295.38 ± 250.09 1604.090 ± 208.06 0.017
PRAS40 462.13 ± 31.84 438.298 ± 15.13
P70S6K 1204.38 ± 130.96 1258.14 ± 170.01
Protein (phospho)
pS473-Akt 273.47 ± 720.05 252.78 ± 33.53
pS9-GSK3β 612.40 ± 155.72 636.30 ± 46.82
pT246-PRAS40 65.65 ± 5.42 78.07 ± 7.37
pTpS421/424-p70S6K 184.44 ± 23.30 114.32 ± 19.48
Protein (Phospho/Total) ∗ 100
pS473-Akt/Akt 1.43 ± 0.32 1.12 ± 0.14
pS9-GSK3β/GSK3β 28.42 ± 5.12 44.02 ± 8.15 0.038
pT246-PRAS40/PRAS40 14.29 ± 2.26 17.65 ± 1.46
pTpS421/424-p70S6K/p70S6K 13.91 ± 4.14 9.01 ± 0.97
Liver homogenates were used to measure immunoreactivity by multiplex ELISA. Phospho/total signaling protein levels were calculated. Immunoreactivity
was normalized to protein concentration and data are expressed as mean ± SEM of fluorescence light units (arbitrary). Intergroup comparisons were made
using t-tests. Significant P values are indicated in the right column.
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Table 4: Eﬀects of chronic ethanol consumption on hepatic expression of proceramide genes-biosynthetic pathways.
Protein Control Ethanol P value
CerS1 0.542 ± 0.162 1.145 ± 0.228 0.025
CerS2 3634 ± 509.2 3982 ± 450
CerS4 160.2 ± 36.36 172.7 ± 22.86
CerS5 1.62 ± 0.22 3.62 ± 0.27 <0.0001
CerS6 15.70 ± 3.59 33.52 ± 5.48 0.0071
SPTLC-1 121.4 ± 9.29 253.3 ± 26.26 0.0001
SPTLC-2 2615 ± 444.8 3187 ± 309.5
SMPD-1 685.7 ± 133.9 1214 ± 244.8 0.036
SMPD-3 765.4 ± 140.5 1353 ± 216.6 0.019
CERD2 6.524 ± 2.439 1.887 ± 0.3439 0.04
CERD3 5.583 ± 1.458 6.896 ± 1.853
UGCG 282.6 ± 68.27 609.9 ± 174.5 0.0006
GM3Syn 56.21 ± 7.80 72.32 ± 6.981 0.006
RNA extracted from normal or chronic alcoholic livers (N = 8/group) was reverse transcribed, and the cDNAs were used to measure gene expression by
qPCR analysis with gene-specific primer pairs in a duplex qPCR reaction, in which the genes of interest were co-amplified with HPRT for normalization (see
Section 2 and Table 1). Table represents relative levels of gene expression for Ceramide synthases (CERS), UDP glucose ceramide glycosyltransferase (UGCG),
ceramidases (CERD), GM3-synthase, serine palmitoyl transferase subunits (SPTLC), sphingomyelinases (SMPD). Intergroup comparisons were made using
Student’s t-tests and significant P values are shown over the graphs.
proinflammatory cytokines/chemokines was unexpected vis-
a`-vis the histopathological features of chronic active ALD.
However, these findings correspond with results in previous
experimental models of chronic ethanol feeding [11, 44].
Similarly, given the extensive degree of fibrosis, the finding
of reduced levels of pro-fibrogenic markers was not expected,
but it may reflect a host compensatory eﬀort to restore liver
structure.
4.2. Role of Insulin Resistance/Impaired Insulin Signaling.
Previous in vitro and experimental animal model studies
demonstrated that short-term ethanol exposure or chronic
ethanol feeding impairs insulin and IGF-1 signaling by
inhibiting tyrosine phosphorylation of the insulin and IGF-
1 receptors, and IRS-1 [45–50]. Impaired signaling through
insulin and IGF-1 receptors was shown to be associated
with reduced ligand-receptor binding and compensatory
upregulation of the receptors, both at mRNA and protein
levels [46, 48]. These eﬀects correlated with inhibition of
downstream signaling through Ras/Raf/Erk MAPK [45, 47,
49, 50], reduced DNA synthesis, and impaired capacity for
the liver to regenerate following partial hepatectomy [48,
51]. In addition, the associated reduced transmission of
signals downstream through the PI3K-Akt pathway increased
apoptosis, DNA damage, mitochondrial dysfunction, and
oxidative stress [46, 48, 52, 53].
The significantly increased levels of the insulin, IGF-1
and IGF-2 receptor expression in human cases of chronic
ALD reflect insulin/IGF resistance. Correspondingly, the
ratio of phosphorylated/total IGF-1 receptor was signifi-
cantly reduced, confirming that chronic ALD impairs signal-
ing through hepatic IGF-1 receptors in humans. Moreover,
the significantly reduced expression of IGF-2 polypeptide
in chronic ALD indicates that IGF-2 signaling was also
impaired, but due to the combined eﬀects of trophic
factor deficiency and receptor resistance. The finding that
IRS-1 and IRS-4 expressions were significantly reduced in
chronic ALD indicates that insulin/IGF receptor signaling
was further impaired by reduced capacity to transmit signals
downstream through IRS docking proteins. An additional
abnormality contributing to hepatic insulin/IGF resistance
in human chronic ALD was the significantly increased levels
of S312 phosphorylation of IRS-1; S312 phosphorylation
inhibits IRS-1 signaling [42]. This is the first study to
demonstrate impairments in insulin/IGF/IRS signaling in
human chronic ALD. However, earlier studies in which
mainly peripheral blood and leukocytes were available for
study showed that patients with alcoholic cirrhosis had
peripheral insulin resistance [54–59] with binding and
postbinding defects in insulin target organ cells [54, 55,
59]. Moreover, analysis of brains from human alcoholics
demonstrated chronic insulin resistance in structural targets
of alcohol-induced neurodegeneration [37]. Therefore, these
earlier studies provide evidence that ethanol-induced insulin
resistance is a multisystem disease that is somehow linked to
chronic progressive liver disease. The question is, “what is the
mechanism?”
To examine the eﬀects of impaired insulin/IGF/IRS
signaling through the downstream Akt pathway, we used
multiplex ELISAs to measure total and phosphorylated levels
of Akt, GSK-3β, PRAS40, and p70S6K. In contrast to the
findings in experimental animals in which impairments
in insulin/IGF/IRS signaling were associated with reduced
AKT and increased GSK-3β activation [48], human chronic
ALD was not associated with significant impairments in
signaling through survival or metabolic pathways. Instead,
the findings of increased Akt and phospho-Akt, but similar
phospho/total Akt relative control, and reduced total GSK-
3β, phospho-Ser9/GSK-3β, and phospho-Ser9/total GSK-3β
indicate that Akt activation was preserved while GSK-3β
was relatively inhibited. Therefore, survival and metabolic
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Figure 3: Eﬀects of chronic ALD on proceramide pathway activation in liver. Using a fluorogenic assay, (a) neutral, (b) acid, and (c) alkaline
sphingomyelinase activities were measured in homogenates of liver from control or chronic ALD subjects. Hepatic ceramide profiles were
measured in lipid extracts by LC/MS/MS. (d) CerC14:0, (e) CerC16:0, (f) CerC18:0, (g) CerC20:0, and (h) CerC24:0 levels are expressed
as pg/mg protein. (i) Total ceramide immunoreactivity was measured by direct-binding ELISA. Intergroup comparisons were made using
Student’s t-tests and significant P values are shown over the graphs.
signaling through the Akt pathway were found to be
intact in human chronic ALD. Similarly, activation of
the mTOR networks via p70S6k and PRAS40 was intact.
The discrepancy between the impairments in upstream
signaling through insulin/IGF/IRS and intact downstream
signaling could be explained by the fact that other signaling
mechanisms, including thosemediated by hepatocyte growth
factor or epidermal growth factor, can also activate Akt
pathways independent of IRS-dependent networks [60, 61].
Future studies will characterize the mechanisms by which
prosurvival and prometabolic signaling are maintained vis-
a`-vis chronic ALD-induced inhibition of insulin/IGF/IRS
pathways.
4.3. Role of Ceramides in Chronic ALD. Although hepatic
steatosis is generally regarded as benign and reversible,
persistent injury and inflammation can cause steatohepatitis
to become chronic and progressive. Two factors that prob-
ably contribute to ALD progression include (1) aberrant
shifts in membrane lipid composition leading to disrupted
intracellular signaling [29, 62, 63]; (2) the accumulation of
toxic lipids that mediate cellular pathology via increased
oxidative stress, ROS generation, adduct formation, and
ER stress. Growth in our understanding of how abnor-
mal accumulation and composition of lipids contribute to
chronic insulin resistance diseases has been furthered by
modern lipidomic approaches. For example, besides the
histopathological diﬀerences, nonalcoholic steatohepatitis
(NASH) is distinguished from nonalcoholic fatty liver disease
(NAFLD) based on the composition of lipids accumulated in
hepatocytes [64].
Diacylglycerol (DAG), free fatty acids, free cholesterol,
and ceramides can all have lipotoxic eﬀects in hepatocytes
[31, 65, 66]. However, we focused our studies on the potential
contributions of ceramides in chronic ALD because (1)
ceramides have demonstrated roles in the pathogenesis of
steatohepatitis in experimental models of chronic ethanol or
high-fat diet feeding [10, 11]; (2) ceramides can promote
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Figure 4: Eﬀects of chronic ALD on hepatic ER stress gene activation. RNA extracted from livers of control and chronic ALD subjects (N =
8/group) was reverse transcribed, and the cDNAs were used to measure gene expression by duplex qPCR assays in which the gene of interest
was coamplified with hypoxanthine-guanine phosphoribosyltransferase (HPRT) as control (see Section 2 and Table 1). Graphs depict relative
levels of gene expression for (a) BAX, (b) ER degradation-enhancing α-mannosidase-like protein (EDEM), (c) C/EBP homologous protein
(CHOP), (d) inhibitor of interferon-induced and double stranded RNA activated kinase (p58IPK), (e) glucose regulated protein 78 (GRP78),
(f) activating transcription factor-4 (ATF-4), (g) homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member
1 (HERP), and (h) tryptophanyl-tRNA synthetase (WARS). Intergroup comparisons were made using Student’s t-tests. Significant P values
are shown over the graphs.
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Figure 5: Chronic ALD results in increased hepatic ER stress. ER stress protein expression and phosphorylation were measured by ELISA
using HRP-conjugated secondary antibody and Amplex UltraRed soluble fluorophore. Graphs depict immunoreactivity corresponding to
(a) Bip/GRP78, (b) CHOP, (c) inositol requiring enzyme-1 (IRE-1), (d) calnexin, (e) endoplasmic oxidoreductin-1 (ERO-1), (f) protein
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(Ex 530 nm/Em 590 nm) in a Spectramax M5 microplate reader (FLU = fluorescence light units). Intergroup comparisons were made by
Student’s t-test analysis. Significant P values are shown over the graphs.
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insulin resistance, inflammation, and oxidative stress in vari-
ous insulin resistance disease states [67–69], including Type 2
diabetes and obesity [70–72]; (3) ceramides impair Akt/PKB
signaling through activation of protein phosphatase 2A
(PP2A) which dephosphorylates Akt [18, 73] and inhibition
of protein-kinase-C-ζ- (PKC-ζ-) dependent translocation
of Akt to the plasma membrane, which is required for its
function [22]. Although the Akt pathway was not inhibited in
human chronic ALD, taken in the context of the impairments
detected in experimental models, it is possible that the
abnormality does occur in the earlier and less severe stages of
ALD, but compensatory mechanisms restore these functions
via activation of other signaling networks, for example, those
driven by EGF or HGF. As demonstrated with the multiplex
array analysis, HGF expression was strikingly increased in
chronic ALD relative to control livers.
Corresponding with the findings in experimental mod-
els of alcohol- and high-fat-diet-induced steatohepatitis,
human livers with severe chronic ALD had significantly
increased expression of multiple proceramide genes as
well as increased levels of ceramide immunoreactivity. The
robustness and significance of this response are underscored
by the constitutive upregulation of proceramide genes in
the biosynthetic, catabolic, and salvage pathways, as well as
increased activation of acidic and neutral sphingomyelinases.
Mechanistically, insulin resistance promotes lipolysis, and
increased lipolysis results in the breakdown (hydrolysis)
of complex lipids, thereby promoting increased levels of
ceramide. In addition, ceramides can be generated via
the salvage pathway due to increased levels of precursor
lipids. Conceivably, the pathogenic signaling that activates
lipolysis vis-a`-vis chronic steatohepatitis may also initiate
proceramide cascades by increasing gene expression and
enzymatic activity. The increased levels of ceramide synthase
gene expression could be explained by increased fatty
acid load that characteristically occurs with steatohepatitis,
irrespective of etiology [10, 11, 74].
We extended our analyses by characterizing the ceramide
profiles in liver tissue using LC-MS/MS. The rationale was
that (1) ceramides associated with specific fatty acids can
have diverse biological functions and can be generated
in response to diverse stimuli [75, 76]; (2) intracellular
partitioning of fatty acids and their metabolites plays a role in
mediating insulin resistance and lipotoxicity [77]. Coupling
liquid chromatography with tandem mass spectrometry
enabled us to identify the diﬀerent ceramide species in liver
based on retention time and specific mass transition using
synthetic reference standards [78].
The LC/MS/MS studies demonstrated that the ceramide
profiles in chronic ALD diﬀered significantly from those in
control livers due to the relatively higher levels of C14:0,
C16:0, C18:0, and C20:0. Previously it was shown that
increased levels of C16:0, and also C24:0 ceramides could
promote cell death [79, 80], while C18:0 ceramide inhibits
cell growth [81]. Therefore, the ongoing cell death associated
with chronic progressive ALD in humans could be mediated
in part by increased levels of C16:0 ceramide. Mechanisti-
cally, CERS1 has a high specificity for C18:0-CoA generating
C18:0-ceramide, and CERS2 and CERS4 mainly synthesize
C20:0-, C22:0-, C24:1-, C24:0-, C26:1-, and C26:0-ceramide.
In contrast, shorter chain ceramides like C14:0, C16:0 are
primarily generated by CerS5 and CerS6 [76]. The qRT-
PCR analyses demonstrated significantly higher levels of
CERS1, CERS5, and CERS6 in human chronic ALD, which
could partly account for the associated shifts in hepatic
ceramide profiles. As the field of lipidomics grows, our
ability to interpret these types of results in relation to disease
pathogenesis, including insulin resistance, lipotoxicity, and
inflammation will improve. In addition, we may arrive at
the point where targeting specific proceramide mediators
can be used to therapeutically modulate ceramidemembrane
composition.
4.4. ER Stress in Progressive ALD. Insulin resistance, inflam-
mation, and ceramide accumulation can promote ER stress,
and ER stress exacerbates insulin resistance, inflammation,
oxidative stress, and ceramide accumulation [35, 82–88].
Moreover, ethanol exposure in experimental animal models
leads to increased activation of ER stress responses in
liver [36, 89, 90]. The studies herein demonstrate that
in human chronic progressive ALD, ER stress signaling is
strikingly upregulated via multiple mechanisms including
(1) Bip/GRP78, which is an important chaperone protein;
(2) IRE-1α, which activates JNK; (3) PERK, which promotes
global arrest of protein synthesis, translation of ATF4, and
upregulation of CHOP; (4) CHOP, which activates caspases
and inhibits Bcl2 prosurvival function by activating BAX.
The increased levels of ATF-4 in chronic ALD correspond
with the significantly higher levels of chaperones and other
components of the folding and ERAD machinery, that is,
PDI and GRP78. In addition, chronic ALD was found to be
associated with significantly increased expression of calnexin
and ERO-1a. Calnexin binds glycosylated proteins after they
pass into the ER, while ERO1 and BAX are activated by
CHOP. Therefore, consequences of constitutive activation of
the UPR in chronic ALD progression include (1) increased
apoptosis via CHOP [91]; (2) disruption of calcium and
redox homeostasis [34]; (3) further dysregulation of lipid
homeostasis [92] leading to enhanced production of choles-
terol and triglycerides via activation of the transcription
factor SREBP.
5. Summary and Conclusions
Human chronic progressive ALD is associated with impaired
insulin and IGF signaling through insulin/IGF receptors,
IRS-1, and IRS-4. However, downstream signaling through
Akt pathways were found intact, probably due to com-
pensatory adaptive responses such as signaling through
other receptors such as EGF or HGF. In contrast to the
histopathological findings, chronic ALD was not associated
with increased activation of proinflammatory cytokines or
chemokines or profibrogenic markers. The most striking
abnormalities in human livers with advanced chronic ALD
were prominent activation of proceramide mechanisms with
ceramide accumulation and altered ceramide profiles, and
increased activation of the UPR via several pathways and
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at multiple levels of the network. The aberrant shifts in
ceramide profiles could have contributed to the insulin
resistance and continued activation of prodeathmechanisms.
At the late stages of disease examined, it is not possible
to designate any single mechanism as the cause of ALD
progression. However, the findings in experimental animal
models suggest that one of the earliest abnormalities in
chronic steatohepatitis is insulin resistance. We hypothe-
size that once steatohepatitis becomes suﬃciently severe
and long-standing, hepatic insulin resistance mechanisms
with activation of mal-signaling cascades become initiated
whereby lipolysis leads to increased ceramide generation
and accumulation in membranes including the ER and
plasma membrane. Ceramide accumulation in the ER pro-
motes ER stress, and ceramide incorporation into lipid
rafts exacerbates insulin resistance, inflammation, oxidative
stress, and proapoptosis signaling. Increased oxidative stress
leads to ROS formation, lipid peroxidation, DNA damage,
and cell death. Altogether, the findings herein suggest that
therapeutic prevention or reduction of ALD progression
requires multipronged strategies to reverse or stabilize the
consequences of hepatic insulin resistance and dysregulated
lipid metabolism.
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